EUVIMEDEUVIMED entdecken
Crossref

A Potential Boron Neutron Capture Therapy Agent Selectively Suppresses High-Grade Glioma: In Vitro and in Vivo Exploration

Catalina Alamón, Belén Dávila, María Fernanda García iD, Susana Nievas, María Alejandra Dagrosa, Silvia Thorp, Mariángeles Kovacs, Emiliano Trias, Ricardo Faccio iD, Martín Gabay, Nidal Zeineh, Abraham Weizman und 5 weitere

Molecular Pharmaceutics · 2023

DOI: 10.1021/acs.molpharmaceut.3c00152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Catalina Alamón und 16 weiteren Autor:innen. Beteiligte Einrichtung: Grupo de Química Orgánica Medicinal, Instituto de Química Biológica, Facultad de Ciencias, Universidad de la República, Montevideo 11400, Uruguay. Hauptthemen laut MEDLINE: Brain Neoplasms, Boron Neutron Capture Therapy, Glioma, Glioblastoma. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Institut Pasteur de Montevideo, Agencia Nacional de Investigaci?n e Innovaci?n, Universidad de la Rep?blica Uruguay.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM), as the most central nervous system (CNS) intractable disease, has spoiled millions of lives due to its high mortality. Even though several efforts have been made, the existing treatments have had limited success. In this sense, we studied a lead compound, the boron-rich selective epidermal growth factor receptor (EGFR)-inhibitor hybrid 1, as a potential drug for GBM treatment. For this end, we analyzed the in vitro activity of hybrid 1 in a glioma/primary astrocytes coculture, studying cellular death types triggered by treatment with this compound and its cellular localizations. Additionally, hybrid 1 concentrated boron in glioma cells selectively and more effectively than the boron neutron capture therapy (BNCT)-clinical agent 10B-l-boronophenylalanine and thus displayed a better in vitro-BNCT effect. This encouraged us to analyze hybrid 1 in vivo. Therefore, immunosuppressed mice bearing U87 MG human GBM were treated with both 1 and 1 encapsulated in a modified liposome (recognized by brain-blood barrier peptide transporters), and we observed a potent in vivo per se antitumor activity (tumor size decrease and animal survival increase). These data demonstrate that 1 could be a promising new targeted therapy for GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsBoron Neutron Capture TherapyGliomaGlioblastomaMiceHumansAnimalsBoronBoron Compounds

Stichwörter der Autor:innen

boron neutron capture therapyepidermal growth factor receptorsglioblastoma

Substanzen

BoronBoron Compounds

Autor:innen und Institutionen

  • Grupo de Química Orgánica Medicinal, Instituto de Química Biológica, Facultad de Ciencias, Universidad de la República, Montevideo 11400, Uruguay.
  • Laboratorio de Neurodegeneración, Institut Pasteur de Montevideo, Montevideo 11400, Uruguay.
  • Área de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo 11400, Uruguay.
  • Área Física, DETEMA, Facultad de Química, Universidad de la República, Montevideo 11800, Uruguay.
  • Molecular Pharmacology, Faculty of Medicine, Technion Institute of Technology, Haifa 3200003, Israel.
  • Institut de Ciències dels Materials de Barcelona-CSIC, Campus UAB, Bellaterra 08193, Spain.

ORCID-Profile: María Fernanda García, Ricardo Faccio, Francesc Teixidor, Clara Viñas, Hugo Cerecetto

Förderung

  • Institut Pasteur de Montevideo
  • Agencia Nacional de Investigaci?n e Innovaci?n
  • Universidad de la Rep?blica Uruguay
  • Comisi?n Sectorial de Investigaci?n Cient?fica
  • FOCEM

Zitieren

APA

Alamón, C., Dávila, B., García, M. F., Nievas, S., Dagrosa, M. A., Thorp, S., Kovacs, M., Trias, E., Faccio, R., Gabay, M., Zeineh, N., Weizman, A., Teixidor, F., Viñas, C., Gavish, M., Cerecetto, H., & Couto, M. (2023). A Potential Boron Neutron Capture Therapy Agent Selectively Suppresses High-Grade Glioma: In Vitro and in Vivo Exploration. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00152

Vancouver

Alamón C, Dávila B, García MF, Nievas S, Dagrosa MA, Thorp S, et al. A Potential Boron Neutron Capture Therapy Agent Selectively Suppresses High-Grade Glioma: In Vitro and in Vivo Exploration. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00152

BibTeX
@article{Alamn2023,
  author = {Alamón, Catalina and Dávila, Belén and García, María Fernanda and Nievas, Susana and Dagrosa, María Alejandra and Thorp, Silvia and Kovacs, Mariángeles and Trias, Emiliano and Faccio, Ricardo and Gabay, Martín and Zeineh, Nidal and Weizman, Abraham and Teixidor, Francesc and Viñas, Clara and Gavish, Moshe and Cerecetto, Hugo and Couto, Marcos},
  title = {A Potential Boron Neutron Capture Therapy Agent Selectively Suppresses High-Grade Glioma: In Vitro and in Vivo Exploration},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  doi = {10.1021/acs.molpharmaceut.3c00152}
}
Kostenlos starten →